Coherus Q2 FY26 net loss narrows 25.67% to $33.3 million; revenue rises 39.51% to $14.3 million
CHRS•Q2 revenue and loss narrow
- Coherus Oncology posted Q2 2026 revenue of USD 14.3 million, up 39.53% from a year earlier.
- Net loss from continuing operations narrowed to USD 33.3 million, or USD 0.22 per share, from USD 44.9 million, or USD 0.39 per share.
LOQTORZI growth and cost trends
- LOQTORZI net revenue rose 15% from Q1 2026 to USD 13.6 million, with strong demand and the most new patient starts since launch.
- R&D expense fell to USD 21.4 million from USD 26.3 million, on reduced headcount and lower trial and manufacturing costs.
- Cash, cash equivalents and marketable securities totaled USD 105.3 million at June 30, 2026, down from USD 172.1 million at Dec. 31, 2025.
Related News
American Integrity Insurance CEO Robert C. Ritchie sells USD 1.31 million in common shares
AII•
BlackRock Capital Allocation Term Trust CCO Charles Park files initial beneficial ownership statement
BCAT•
